Sagent Pharmaceuticals: Sagent Pharmaceuticals launches phase 2 trial to evaluate Camostat Mesilate for Covid-19 treatment

"We thank the FDA for expediting our new Investigational New Drug (IND) application and approving this clinical trial to evaluate Camostat as a treatment for patients suffering from The post Sagent Pharmaceuticals launches phase 2 trial to evaluate Camostat Mesilate for Covid-19 treatment appeared first on Pharmaceutical Business review.